- Home
- ATOS vs AVTX Comparison
ATOS vs AVTX Comparison
Compare ATOS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- AVTX
- Stock Information
- Founded
- ATOS 2009
- AVTX 2011
- Country
- ATOS United States
- AVTX United States
- Employees
- ATOS N/A
- AVTX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- AVTX Health Care
- Exchange
- ATOS Nasdaq
- AVTX Nasdaq
- Market Cap
- ATOS 96.8M
- AVTX 88.4M
- IPO Year
- ATOS 2012
- AVTX 2015
- Fundamental
- Price
- ATOS $0.65
- AVTX $6.85
- Analyst Decision
- ATOS Strong Buy
- AVTX Strong Buy
- Analyst Count
- ATOS 3
- AVTX 7
- Target Price
- ATOS $7.00
- AVTX $34.33
- AVG Volume (30 Days)
- ATOS 520.3K
- AVTX 110.3K
- Earning Date
- ATOS 03-25-2025
- AVTX 05-12-2025
- Dividend Yield
- ATOS N/A
- AVTX N/A
- EPS Growth
- ATOS N/A
- AVTX N/A
- EPS
- ATOS N/A
- AVTX N/A
- Revenue
- ATOS N/A
- AVTX $441,000.00
- Revenue This Year
- ATOS N/A
- AVTX N/A
- Revenue Next Year
- ATOS N/A
- AVTX N/A
- P/E Ratio
- ATOS N/A
- AVTX N/A
- Revenue Growth
- ATOS N/A
- AVTX N/A
- 52 Week Low
- ATOS $0.65
- AVTX $5.99
- 52 Week High
- ATOS $2.31
- AVTX $20.85
- Technical
- Relative Strength Index (RSI)
- ATOS 31.82
- AVTX 41.31
- Support Level
- ATOS $0.66
- AVTX $7.88
- Resistance Level
- ATOS $0.71
- AVTX $9.00
- Average True Range (ATR)
- ATOS 0.04
- AVTX 0.83
- MACD
- ATOS -0.00
- AVTX -0.03
- Stochastic Oscillator
- ATOS 0.00
- AVTX 1.47
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).